Smart glasses for detecting auditory hallucinations in schizophrenia patients, aimed at controlling and improving symptoms during disease exacerbation

Smart glasses with integrated sensors and feedback mechanisms help schizophrenia patients distinguish auditory hallucinations, alleviating symptoms and enhancing their quality of life by providing real-time physiological monitoring and non-pharmacological interventions.

WO2026234439A1PCT designated stage Publication Date: 2026-11-12HASHEMI ALIREZA +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2025/062830
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-01-27
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing technologies fail to effectively distinguish auditory hallucinations from reality and manage symptoms in schizophrenia patients, lacking comprehensive physiological monitoring and non-pharmacological intervention methods.

Method used

Smart glasses equipped with thermal and image processing cameras, sensors for heart rate, blood oxygen, and eye deviation, along with audio and tactile feedback, to detect and alleviate auditory hallucinations by providing soothing stimuli and location tracking.

Benefits of technology

The smart glasses enable patients to differentiate hallucinations from reality, reduce anxiety, and control symptoms through continuous monitoring and personalized feedback, potentially reducing treatment costs and improving quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2025062830_12112026_PF_FP_ABST
    Figure IB2025062830_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention entitled "Smart Glasses for Detecting Auditory Hallucinations in Schizophrenia Patients, Aimed at Controlling and Improving Symptoms During Disease Exacerbation" relates to the field of medicine and provides a device for assisting patients with schizophrenia in detecting auditory hallucinations. Schizophrenia is a severe mental disorder affecting about one percent of the global population and is associated with hallucinations, delusions, and behavioral disturbances. Current treatments are costly and not effective for all patients. The proposed solution is a pair of smart glasses (1) comprising image processing cameras (1-2), a thermal imaging module (1-3), flashing LEDs (1-4), an OLED display (1-5), switches (1-6), vibration motors (1-7), speakers (1-8), a lithium battery charge control module (1-9), an SD card reader module for SIM and memory cards (1-10), a microphone (1-11), a processor (1-12), a lithium battery (1-13), a body temperature sensor (1-14), and a pulse oximeter / heart rate sensor (1-15), while communication is enabled by a GSM module (1-16). The system detects hallucination patterns, provides multimodal feedback, and supports symptom control, thereby improving patient outcomes during disease exacerbation.
Need to check novelty before this filing date? Find Prior Art

Description

DescriptionTitle of Invention: Smart Glasses for Detecting Auditory Hallucinations in Schizophrenia Patients, Aimed at Controlling and Improving Symptoms During Disease ExacerbationTechnical Field

[0001] The present invention relates to the field of medicine and more particularly to schizophrenia.Background Art

[0002] An invention numbered WO2021151188, disclosed in 2021 in Canada, entitled “Tool for assisting individuals experiencing auditory hallucinations to differentiate between hallucinations and ambient sounds,” provides feedback to the user regarding the presence or absence of perceived sounds.An invention numbered CN105816170B, disclosed in 2016 in China, entitled “Schizophrenia early detection assessment system based on wearable NIRS- EEG,” utilizes EEG and NIRS to collect information on brain function.An invention numbered IN202211072524, disclosed in 2022 in India, entitled “An loT-based aid for monitoring hallucinations and assisting in cognitive rehabilitation of schizophrenia patients,” captures images of locations to evaluate visual hallucinations.An invention numbered CN104545939A, disclosed in 2015 in China, entitled “Head-wearing schizophrenia auxiliary diagnosis device,” processes the data and transmits the information wirelessly to the patient’s phone or directly to the physician’s email.An invention numbered US20220218198A1, disclosed in 2022 in the United States, entitled “Method and system for measuring pupillary light reflex with a mobile phone,” captures pupillary characteristics, then evaluates the pupillary light reflex (PLR).An invention numbered US10016130B2, disclosed in 2018 in the United States, entitled “Eye tracker system and methods for detecting eye parameters,” detects and evaluates eye features to determine various psychological conditions.An invention numbered US20220095974A1, disclosed in 2022 in the United States, entitled “Mental state determination method and system,” determines the mental state by comparing physiological data with pre-trained neural algorithms. An invention numbered CN109223006A, disclosed in 2019 in China, entitled “System for diagnosing schizophrenia,” includes a pupil size measurement device and a stimulation apparatus in a diagnostic model for schizophrenia.An invention numbered W02023037708A1, disclosed in 2023 in Japan, entitled “A system, computer program and method,” is a device that collects head movement and speech-related data and matches it against schizophrenia parameters.An invention numbered KR20190033145A, disclosed in 2019 in South Korea, entitled “System for healthy lifestyle for schizophrenia patients using application on smart device,” collects biometric data to improve the lifestyle of schizophrenia patients.An invention numbered CN112168187A, disclosed in 2021 in China, entitled “Diagnosis index, diagnosis model and diagnosis system for schizophrenia,” analyzes eye-gaze patterns and identifies distinctive visual attention patterns. An invention numbered CN112869744A, disclosed in 2021 in China, entitled “Schizophrenia auxiliary diagnosis method, system and storage medium,” utilizes eye movement data and applies ML algorithms to predict diagnostic outcomes. An invention numbered RU2766049C1, disclosed in 2022 in Russia, entitled “Method for complex group rehabilitation of patients with schizophrenia,” improves the quality of life for patients with schizophrenia through aromatherapy sessions.An invention numbered KR101070122B1 , disclosed in 2011 in South Korea under the title “A device and method for diagnosing schizophrenia using heart rate variability measures,” diagnoses schizophrenia through the measurement of HRV.An invention numbered US20240285206A1, disclosed in 2024 in the United States, titled “Device and method for dynamic determination of medical subtype,and subtype driven personalized medical care,” analyzes real-time symptom biometric data to provide accurate diagnoses.An invention numbered US20220395222A1, disclosed in 2022 in the United States under the title “Systems and methods for detection and prevention of emergence of agitation,” collects physiological data to estimate an impending agitation episode.An invention numbered US2017135577A1 , disclosed in 2017 in the United States under the title “Health assessment via eye movement biometrics,” identifies brain injuries like schizophrenia from analyzing features of recorded eye-movement signals.An invention numbered US10258291, disclosed in 2019 in the United States under the title “Systems and methods for evaluation of neuropathologies,” diagnoses Alzheimer's disease by processing EEG signals during exposure.An invention numbered CN109480865A, disclosed in 2019 in China under the title “System for diagnosing schizophrenia by utilizing eye movement index,” constructs an assessment model that achieves schizophrenia diagnosis accuracy of up to 80%.An invention numbered CN112057087A, disclosed in 2020 in China under the title “Method and device for evaluating autonomic nerve function of schizophrenia high-risk population,” identifies schizophrenia risk through the autonomic nervous system.An invention numbered KR1020210015365, disclosed in 2021 in South Korea under the title “Al speaker capable of diagnosing and treating schizophrenia,” detects signs of schizophrenia using an approach that analyzes the information. An invention numbered JP2008206830A, disclosed in 2008 in Japan under the title “Schizophrenia diagnosing apparatus and program,” utilizes a camera-based pupil imaging system to assess the likelihood of schizophrenia.An invention numbered CN117617973, disclosed in 2024 in China under the title “Eye movement feature self-adaption-based schizophrenia early recognition method and system,” conducts neurological and visual tests toward personalized diagnostics.An invention numbered WO2016038937A1 , disclosed in 2016 in Japan under the title “Mental disease determination device and mental disease determination method,” analyzes the eye motion trajectories for determining the stage of mental disorders.An invention numbered CN110097930A, disclosed in 2019 in China under the title “Schizophrenia medical data processing method, device, system, server and medium,” utilizes a browser-based interface to analyze and process patient data. An invention numbered US11763929, disclosed in 2023 in the United States under the title “Medical tool aiding diagnosed psychosis patients in detecting auditory psychosis symptoms associated with psychosis,” helps the patient detect auditory hallucinations by capturing and analyzing environmental sounds.An invention numbered US0040356A1, disclosed in 2011 in the United States under the title “Methods for treating psychiatric disorders using light energy,” treats disorders beyond depression by analyzing the lateral visual field and the emotional capacity.An invention numbered US20210204853, disclosed in 2021 in the United States under the title “Systems and methods for cognitive diagnostics in connection with major depressive disorder and response to antidepressants,” utilizes Al classification algorithms to evaluate mental health status and response to treatment.An invention numbered US5963294A, disclosed in 1999 in the United States under the title “Method for using therapeutic glasses for stimulating a change in the psychological state of a subject,” influences perceptual and emotional processing through visual field modulation.An invention numbered CN213758220U, disclosed in 2021 in China under the title “Human body state monitoring device and bracelet,” emits an alert signal when abnormal physiological patterns indicative of schizophrenia illness are detected.An invention numbered US10349899B2, disclosed in 2019 in the United States under the title “System and method for predicting hallucinations,” provides a quantitative index for assessing the probability of hallucination onset through the processing of individual movement interactions.An invention numbered US11245996B1 , disclosed in 2022 in the United States under the title “Apparatus and method for treating a neurological disorder of the auditory system,” treats neurological and auditory disorders through analyzing auditory signals.Summary of Invention

[0003] The invention entitled “Smart Glasses for Detecting Auditory Hallucinations in Schizophrenia Patients, Aimed at Controlling and Improving Symptoms During Disease Exacerbation” pertains to the medical field and is specifically associated with schizophrenia. Schizophrenia is a serious mental disorder that affects approximately one percent of the global population. It has been recognized as the 12th most disabling disorder worldwide and severely impacts the personal and social lives of affected individuals. The disease is characterized by hallucinations, delusions, and behavioral disturbances, significantly reducing patients’ quality of life. It also considerably increases the risk of suicide and decreases life expectancy. The treatment costs for schizophrenia are extremely high, and current therapeutic approaches are not effective for all patients. The proposed invention is a pair of smart glasses that assist schizophrenia patients in detecting auditory hallucinations, relieving symptoms, managing the disease, and improving overall well-being by utilizing advanced technologies, including a thermal camera, an image processing method, a voice assistant, heart rate, blood pressure, and body temperature sensors, sensory stimulators such as sound, light, and vibration modules, a microphone, and a Global Positioning System (GPS). This invention is specifically designed for use by patients diagnosed with schizophrenia.Technical Problem

[0004] Schizophrenia, affecting approximately 1% of the global population, is a severe mental illness that was recognized as the 12th most disabling disorder worldwide in 2016 (Charlson et al., 2018). Patients with schizophrenia often face uncertainty in their thoughts and actions (Humpston, 2022). Schizophrenia is characterized by positive symptoms such as hallucinations and delusions (often paranoid) and negative symptoms including flat affect, limited speech, loss of pleasure, and social withdrawal. A definitive diagnosis requires that symptoms and signs must be present for a month, and some of them must be ongoing for atleast six months, accompanied by significant social and occupational dysfunction. Both types of symptoms impact patients' families, and, on the other hand, patients experience low quality of life and challenges in daily living due to frequent hospitalizations and insufficient social support (Correll & Schooler, 2020). Auditory hallucinations, or paracusias, are prevalent positive symptoms of schizophrenia, affecting 60 to 90 percent of patients. These hallucinations can manifest as various sounds, such as incoherent voices, threatening noises, or whispers related to the patient (Bhandari, 2012). The exact causes of auditory hallucinations are not entirely understood, but several possible factors have been mentioned: brain abnormalities or injuries, genetic predispositions (Owen et al., 2016), and increased dopamine in some areas of the brain (Grace & Gomes, 2019).In patients with schizophrenia experiencing auditory hallucinations, physiological changes such as increased autonomic nervous system activity and stress responses occur. Notable reactions include attention span issues, diminished thought control and decision-making (Thakkar et al., 2018), anxiety (Kanungpairn et al., 2007), eye deviation (Cooklin et al., 1983), and increased corneal temperature (Shiloh et al., 2005). There is also impaired autonomic function affecting heart rate, blood pressure, and breathing, alongside panic attacks (Gabinio et al., 2017) and hyponatremia (Atsariyasing & Goldman, 2014). Various factors contribute to the exacerbation of auditory hallucinations, including severe stress, substance use (Ward et al., 2023), social isolation (Butter et al., 2017), and environmental conditions like high ambient temperature (Shiloh et al., 2007). High rates of comorbid anxiety (65%), panic attacks (45%), and depression (50%) are prevalent among patients with schizophrenia. About 90% of patients with schizophrenia smoke to reduce or relieve their symptoms. However, evidence indicates that smoking may exacerbate symptoms rather than relieve them (Huang et al., 2019). Schizophrenia has a high suicide risk, with 1 in 20 individuals committing suicide. There is a strong association between auditory hallucinations and suicide attempts, with 4-10% of suicidal behaviors in schizophrenia reported to be in response to auditory hallucinations (Palmer et al., 2005).Medications can effectively manage symptoms of schizophrenia, but most antipsychotics lead to neurological or physical side effects (Farwell et al., 2004). While pharmacological treatments target auditory hallucinations, 30-50% of patients are resistant (Howes et al., 2017). The financial burden of schizophrenia is substantial, costing over $150 billion annually in the U.S. (Cloutier et al., 2016) and €93.9 billion in Europe (Gustavsson et al., 2011 ).Studies indicate that 25 to 50 percent of schizophrenia patients experience ongoing auditory hallucinations even post-treatment. This persistence of symptoms highlights the need for behavioral symptom management strategies, such as distraction techniques and psychosocial interventions, alongside pharmacological treatments. Behavioral strategies, including relaxation techniques and music listening, especially classical music, have been shown to effectively mitigate symptoms and the duration and intensity of hallucinations (Buccheri et al., 2004). Additionally, music interventions are linked to improved emotional regulation, which is pivotal in addressing abnormalities associated with schizophrenia (Wahyuningtyas et al., 2022). Promoting functional recovery is essential, enabling patients to reintegrate into society and lessening social and healthcare burdens (Emiroglu et al., 2009).Many tools and devices have been invented in the field of diagnosing schizophrenia in individuals. These devices have generally been created to facilitate and accurately diagnose the disease by a doctor or to differentiate between hallucinations and reality for the patient. Existing inventions have only used sensors to record environmental sounds or monitor one or more physical factors, and no single invention has been planned for the main scientific physiological reactions that arise when an auditory hallucination occurs in a person with schizophrenia. Furthermore, existing inventions in the field of distracting the senses, reducing anxiety, creating calmness, and relieving discomfort in a patient with schizophrenia during auditory hallucination have not been devised using non-pharmacological methods.The proposed invention attempts to address the aforementioned deficiencies in the field of schizophrenia in the form of smart glasses based on continuous monitoring of several key physiological factors and providing audio, visual, and tactile feedback. These glasses are placed on the patient's face and, bycontinuously assessing the heart rate, eye deviation, and corneal temperature, can help him / her distinguish between auditory hallucinations and reality when auditory hallucinations occur. On the other hand, this invention helps patients reduce anxiety caused by hallucinations and provides peace of mind by providing feedback such as playing soothing music, creating vibrations, talking to the voice assistant to invite them to relax, and creating colored lights in the frame of the glasses. Furthermore, these glasses can send the patient's exact location and history to his / her family, close people, or medical team to help him / her in emergencies.The purpose of inventing this device is to help schizophrenia patients distinguish auditory hallucinations from reality.Solution to Problem

[0001] Smart Glasses for Detecting Auditory Hallucinations in Schizophrenia Patients, Aimed at Controlling and Improving Symptoms During Disease Exacerbation, use electronic components to help people with schizophrenia distinguish auditory hallucinations from real sounds when acute symptoms occur, control their symptoms, and maintain peace of mind. The mentioned invention (1) is positioned on the user’s nose via the front part of the frame and on the ears via the temple arms. The front of the frame (1) includes a thermal camera (1-3), image processing cameras (1-2), flashing LED lights (1-4), a microphone (1-11), and other circuits. The frame handles also include two speakers (1-8), two vibration motors (1-7), a display (1-5), a body temperature sensor (1-14), a pulse oximeter module (1-15), a heart rate sensor (1- 15), a GSM module (1-16), a rechargeable battery (1-13), a charging port (1-9), a SIM card and memory card compartment (1-10), buttons for changing device settings (1- 6), and related circuits. In general, it can be stated that the main processor of the device (1-12) is located within the temple arms of the glasses (1), while the various circuit components are intricately integrated throughout the device due to its unified design. To use the glasses (1), the user must first ensure that the device’s battery is fully charged (1-5), then place the glasses (1) on their face and power them on (1-6). After the device (1) is turned on, the image processing cameras (1-2) measure the degree of eye deviation, the thermal camera (1-3) measures the temperature of the cornea, the temperature detection sensor (1-14) measures the body temperature, the pulse oximeter module (1-15) measures the blood oxygen level, and the heart rate sensor (1-15) measures the user's heart rate simultaneously and continuously. When the user is in a normal and stable condition, the device (1) is calibrated based on the user’s physiological indicators, including heart rate, body temperature, corneal temperature, eye deviation, and blood oxygen level. In the next step, if the device (1) detects any change in any of the physiological indicators mentioned in the patient's body (at least 3 out of 5 physiological indicators mentioned) compared to the normal state, the voice assistant (1-11) embedded in the glasses asks the user questions such as "Do you think you are hearing a specific sound?" or "Do you think you are having an auditory hallucination?" to confirm the occurrence of an auditoryhallucination. The device's microphone (1-11) waits for the user to respond. The user’s response “yes,” “no,” or no response at all provides the device (1) with confirmation as to whether changes in any of the body's physiological indicators are caused by auditory hallucinations or have occurred due to physical activities or similar actions. If the user responds “No” to this question, the device (1) continues its operation. If the user responds “Yes,” the voice assistant (1-11) informs the user that they are experiencing an auditory hallucination. In this mode, the voice assistant (1-11) engages in conversation with the user, providing anxiety-reduction techniques and inviting them to remain calm (pre-recorded voice); meanwhile, the environmental sounds are continuously recorded through the microphone (1-11). Also, in this mode, the flashing white and green LED lights (1-4) and the coin-type alert notification vibration motors (1-7) on the temple arms of the glasses (1) are activated, and classical music at a frequency of 80 Hz is played from the speakers (1-8) to help the patient distract from auditory hallucinations and reduce symptoms; the choice of playing 80 Hz music or playing pre-recorded sound is up to the user. On the other hand, the GSM module (1-16) locates the person's exact location and provides the user's real-time condition and precise location coordinates to the family and medical teams in the form of an SMS or emergency call. All the details of the user's information, including general history, changes in physiological symptoms, location, date, time, and number of occurrences of auditory hallucinations and recorded sounds, are stored on the memory card (1-10) embedded in the glasses so that it can be used by doctors, specialists, and even researchers as a patient history for the user's subsequent use in treatment processes. The display (1-5) is also used to display the battery charge level of the glasses, show the antenna status of the glasses, and indicate changes in the speaker volume. In the following section, the circuit connections of the smart glasses will be discussed in detail. Smart Glasses for Detecting Auditory Hallucinations in Schizophrenia Patients, Aimed at Controlling and Improving Symptoms During Disease Exacerbation, relates to the field of medicine and more particularly to schizophrenia. The invention aims to help schizophrenia patients distinguish auditory hallucinations from reality by continuously monitoring the patient's physiological symptoms and providing multiple feedback, thus overcoming theseshortcomings. In other words, these smart glasses help individuals with schizophrenia to recognize auditory hallucinations when they occur, control the symptoms, and relieve the associated distress. The aforementioned invention takes the form of a pair of glasses (1) that have a rechargeable battery (1-13) and a lithium battery charge control module (1-9), which can be charged directly from mains electricity, like common gadgets on the market, and can use internal power (battery) for its operation. Our proposed method is a novel approach based on real-time image processing for the detection of strabismus, specifically designed for integration into smart glasses with a focus on monitoring patients with schizophrenia. The system uses facial key point recognition models such as MediaPipe Face Mesh to identify key points of the eyes (including the iris centers, medial and lateral canthi). By calculating the Euclidean distances between the iris center and these comers, the positional symmetry ratio (S) for horizontal deviation is calculated, where the medial-to-lateral distance ratio is obtained for each eye separately and then compared. Furthermore, vertical deviation (V Dev) is evaluated based on the difference in height of the iris centers relative to a normalized horizontal reference line. Empirical thresholds such as S > 1.15 are applied to detect horizontal asymmetry and V Dev > 0.18 for vertical, and to increase accuracy, we use the Isolation Forest algorithm to detect anomalies in historical data (such as a 30-frame buffer). This method works without the need for a flash or infrared light and displays outputs such as “esotropia,” “exotropia,” or “no deviation” in real time. The key innovation of this method is that it simplifies detection by focusing solely on the geometric symmetry of key points, which eliminates dependence on external factors such as brightness or color. For example, in the post-schizophrenic attack monitoring mode, thresholds are dynamically adjusted (e.g., divided by 1.05) to provide a definitive “attack ended - no deviation” output if both S and V Dev are below the threshold. This approach keeps the computational load low by using lightweight libraries such as OpenCV, NumPy, and scikit-learn, allowing it to be implemented on smart glasses. Furthermore, adjusting the frame delay based on the FPS of the incoming video ensures smooth and near-real-time playback, while debug and calibration modes increase interpretability for experts. Compared to prior art, this method has little similarity to existing literature; for example, the paper (Karaaslan etal., 2023) focuses on the Hirschberg test with corneal reflection detection, which is sensitive to light, while our method relies only on geometric landmarks. Also, the paper (Huang et al., 2021) uses segmentation with HSV and Otsu for pupil detection, but our approach operates without the need for color binarization or the least squares method and shows greater robustness in dynamic environments. These differences highlight the innovation, as our system is optimized for specific applications such as real-time monitoring in schizophrenia (where eye disorders such as strabismus can be biomarkers of attack) and prevents false positives with variance-based confidence scoring.The application of this innovation in smart glasses enables remote monitoring of schizophrenia patients, where eye deviation can be a sign of the onset of an attack, and the system can send alerts to the doctor or family. The system reduces diagnostic delays, especially in underserved areas or for patients with limited mobility, and by integrating into mental health apps, it provides historical data for trend analysis. Experimental validation on demo videos has shown high accuracy (with a confidence threshold >0.5) and has the potential to be extended to other neurological disorders, such as Parkinson's or autism, making this method an innovative tool. This invention generally has four main applications for patients with schizophrenia:1- Detecting symptoms of auditory hallucinations in patients with schizophrenia: According to existing articles and studies, when a patient experiences auditory hallucinations, symptoms are manifested in his / her body; these symptoms include changes in corneal temperature, eye deviations, increased heart rate, changes in blood oxygen, and increased body temperature of the person with schizophrenia. The aforementioned glasses (1) constantly monitor the physiological reactions of the patient's body; eye deviation symptoms are continuously monitored by the image processing camera (1-2), corneal temperature by the thermal camera (1-3), temperature by the body temperature detection sensor (1-14), heart rate and blood oxygen levels by the pulse oximeter sensor and heart rate sensor (1-15), and when changes (at least 3 out of 5 of the physiological symptoms mentioned) occur in these symptoms compared to the calibrated and normal state, the above-mentioned sensorsand modules send a command to the main processor of the glasses (1 -12); of course, at least 3 out of 5 can be changed according to the doctor's opinion; at this stage, the processor (1-12) sends commands to the speaker (1-8), the SD card reader module with read and write capabilities (1 -10), and the microphone module (1-11); during this process, the system audibly asks the user a question: "Do you think you are experiencing auditory hallucinations?" If the user answers "no" to this question, the microphone (1-11) processes the answer, and the device (1) continues to normal operation. If the user answers "yes" to this question, the voice assistant (1-11) informs the user through the speakers (1-8) that he / she is experiencing an auditory hallucination. The patient may have been exercising or in a stressful environment or similar circumstances; the reason for asking the user above ("Do you think you are experiencing auditory hallucinations?") is to determine whether the change in the user's physiological symptoms was due to a change in the user's conditions and environment or the occurrence of auditory hallucinations.2- Controlling and relieving symptoms of a patient with schizophrenia:At this stage, the processor (1-12) has detected that the patient is experiencing auditory hallucinations and sends commands to the flashing LED (1-4), the coin vibration motor (1-7), the speaker (1-8), and the SD card reader module with read and write capabilities (1 -10); meanwhile, the white and green flashing LED lights (1-4) and the coin-type alert notification vibration motors (1-7) on the glasses' arms (1) are activated, and classical music with a frequency of 80 Hz or a personalized sound is played from the speakers (1-8) to help the patient distract his / her attention from the auditory hallucinations, control, and reduce the symptoms of hallucinations.3- Sending the patient's geographical location and history to family members and emergency teams:At the same time as detecting, controlling, and relieving the symptoms of schizophrenia, the processor (1-12) sends a command to the GSM module (1-16), and the module (1-16) begins to locate the user; after detecting the user's geographical location, the module sends the user's historical information (heart rate, blood oxygen level, body temperature, corneal temperature, and eye deviations) alongwith the user's geographical location to family members and emergency teams in the form of SMS and calls so that the family members are informed of the patient's status.4- Managing the patient's treatment process and providing a complete report of the patient's condition during the treatment period:In the meantime, while the patient is experiencing an auditory hallucination, all the details of the user's information, including the general condition, the rate of changes in physiological symptoms, location, date, time, number of occurrences of auditory hallucinations, and environmental sounds recorded by the microphone (1-11), are stored on the memory card via the SD card reader module with read and write capabilities (1-10) so that it can be made available to doctors, specialists, and even researchers as a patient history for the user's subsequent use in treatment processes.Advantageous Effects of Invention

[0006] 1- Suitable for all ages and genders:The ability to use smart glasses for all ages and genders is one of the most important advantages of this technology. This means that this device can help a wide range of people with schizophrenia, and there is no restriction in terms of age and gender.2- The portability of the smart glasses:The portability of the smart glasses is a major advantage that allows schizophrenia patients to use them anytime, anywhere. This feature allows patients to benefit from the advantages of this device in different environments, including home, workplace, and public spaces.3- Usable in all conditions and environments:The ability to use the smart glasses in all conditions and environments is one of the most important features that makes this device an effective therapeutic tool. This feature allows schizophrenia patients to benefit from the advantages of this device in any situation where they encounter auditory hallucinations.4- Reducing schizophrenia treatment costs:By improving symptoms and decreasing the need for hospitalization, these glasses could help reduce treatment costs for schizophrenia patients and the healthcare system.5- Reducing the intensity of auditory hallucinations in schizophrenia patients: By accurately and promptly detecting auditory hallucinations, the smart glasses can reduce the intensity and frequency of these hallucinations using various methods, such as providing visual and auditory stimuli.6- Increasing the quality of life for schizophrenia patientsReducing auditory hallucinations directly affects the quality of life for patients and reduces their anxiety, stress, and feelings of isolation.7- Reducing drug dependence:In some cases, using these smart glasses can help reduce dependence on antipsychotic drugs and reduce their side effects.8- Early detection of disease exacerbation:By continuously monitoring the patient's symptoms, the smart glasses can help in early detection of disease exacerbation and prevent the occurrence of psychological crises.9- Aid tool for Schizophrenia clinicians:These glasses can be used as an aid tool for therapists in diagnosing and treating schizophrenia patients.10- An aid tool for family, friends, and colleagues of a patient with schizophrenia: These smart glasses can act as a bridge between the patient and those around them, helping them to become better informed about the patient's condition and actively participate in their care.11- Collecting valuable data for future research:The data collected by the smart glasses can be used for further schizophrenia research and the development of new treatments.12- Personalizing treatment based on collected data:Based on the data collected by the smart glasses, each patient's treatment can be personalized and tailored to their needs.13- Increasing social productivity by empowering patients to return to society: By improving the quality of life for schizophrenia patients and empowering them to return to society, these smart glasses can help increase social productivity and reduce the economic burden caused by mental illnesses.14- Equipped with thermal and image processing cameras to monitor and process eye variables:By measuring changes in corneal temperature with a smart thermal camera and examining eye deviation with image processing cameras, the smart glasses can detect changes in brain activity that may be a sign of a relapse.15- Equipped with heart rate, blood oxygen, and body temperature sensors:Patients with schizophrenia often suffer from physiological changes that accompany their psychiatric symptoms. These changes can include those in heart rate, blood oxygen, and body temperature. Using physiological sensors, these changes can be accurately and continuously measured, providing valuable information about the patient's condition.16- Equipped with sensitive microphones to detect sudden changes in sound frequency and intensity:Patients with schizophrenia often experience changes in their speech patterns. These changes can include changes in tone of voice, speech rate, loudness, and even speech content. These changes may be early signs of disease relapse, response to treatment, or changes in the severity of symptoms. Using soundsensitive microphones, these changes can be accurately and continuously measured, and valuable information about the patient's condition can be obtained.17- Equipped with a Global Positioning System (GPS):In the event of any danger or emergencies, these smart glasses, upon the patient's request, send the patient's condition and geographical location to the family, caregivers, and medical teams so that they can quickly arrive at the specified location.18- Equipped with an external memory to record and keep the patient's symptoms:Schizophrenia patients often have difficulty expressing their feelings and symptoms. Symptoms may also occur intermittently and with varying degrees of seventy. External memory can be used as a complementary tool to record and keep the patient's symptoms for the diagnosis and treatment process of this disease.19- Relieving the patient during auditory hallucinations with a combination of sound, vibration, and light:The use of sensory stimuli such as sound, vibration, and light can divert the patient's attention from auditory hallucinations to external stimuli, thereby reducing the intensity of hallucinations. These stimuli can affect the activity of the central nervous system and help reduce anxiety and increase relaxation in the patient.Ultimately, these smart glasses, with their user-friendly design and diverse capabilities, allow patients with schizophrenia to independently monitor their health anytime, anywhere. By providing real-time and accurate feedback, these smart glasses help patients feel more in control of their illness and improve their quality of life. In addition, by reducing the need for frequent doctor visits, these glasses can help reduce costs, anxiety, and stress for patients.These smart glasses also take a step beyond previous inventions in the field of schizophrenia treatment by combining advanced technologies such as thermal cameras, image processing, and various sensors. With their unique capabilities, these smart glasses enable precise monitoring of vital signs, early detection of neurological changes, and provision of real-time feedback, thereby significantly improving the quality of life of patients.Brief Description of Drawings

[0001] [Fig.1] illustrates the overall design of the smart glasses for detecting auditory hallucinations.[Fig.1-2] shows the image-processing cameras used to monitor eye deviation.[Fig.1-3] depicts the thermal imaging camera module for corneal temperature detection.[Fig.1-4] presents the flashing LED lights employed for patient distraction.[Fig.1-5] illustrates the OLED display module for system information.[Fig.1-6] shows the switches used for power and settings control.[Fig.1-7] depicts the vibration motors positioned on the temple arms.[Fig.1-8] presents the speakers mounted on the temple arms.[Fig.1-9] illustrates the lithium battery charge control module.[Fig.1-10] shows the SD card reader module for SIM and memory cards.[Fig.1-11] depicts the microphone module for two-way communication.[Fig.1-12] presents the processor responsible for managing sensors and system control.[Fig.1-13] illustrates the lithium battery.[Fig.1-14] shows the body temperature detection sensor.[Fig.1-15] depicts the pulse oximeter and heart rate sensor.[Fig.1-16] presents the GSM module for SMS, voice, and data communication.Description of Embodiments

[0001] In a preferred embodiment, the invention comprises a pair of smart glasses (1) designed to assist patients with schizophrenia in detecting auditory hallucinations and controlling symptoms during disease exacerbation.The smart glasses (1) include image processing cameras (1-2), implemented as two Sony Raspberry Pi Al cameras, configured to detect deviations in the user’s eye movements. A thermal imaging camera module (1-3) is positioned to measure the temperature of the user’s cornea.For visual stimulus, the device incorporates flashing LED lights (1-4) in two colors, white and green, which are activated to distract the patient during hallucination episodes. A 0.91 -inch monochrome OLED display module (1-5) is provided to show system information such as battery charge level, antenna status, audio volume, and other settings.Control of the device is achieved through switches (1-6), three in number, which allow the user to power the device on and off and adjust operational settings. Tactile feedback is delivered by coin-type vibration motors (1-7) mounted on the temple arms of the glasses, which provide alert notifications and distracts the patient (from distressing thoughts).Auditory stimulus is provided by speakers (1-8) located on the temple arms. These speakers are configured to play sound, including classical music at a frequency of 80 Hz, to reduce symptoms by distracting the patient during hallucinations.Power management is achieved through a lithium battery charge control module (1- 9), which extends battery life, and a lithium battery (1-13), the capacity of which may be varied depending on available space within the frame. Data storage and communication are supported by an SD card reader module (1-10), whichaccommodates both a memory card for storing processed information and a SIM card for establishing contact, detecting location, and sending SMS alerts.The device further comprises a microphone module (1-11) for audio input and two-way communication. A processor (1-12), implemented as a Raspberry Pi 4, manages audio and video processing and coordinates the operation of biomedical sensors and other modules.Biomedical monitoring is provided by a body temperature detection sensor (1-14), implemented as a MAX30205 sensor, which continuously measures the patient’s body temperature, and a pulse oximeter and heart rate sensor (1-15), implemented as a MAX30100 module, which continuously monitors heart rate and blood oxygen levels with high sampling accuracy.Communication and location tracking are enabled by a GSM module (1-16), implemented as a SIM800L quad-band unit, which supports SMS, voice calls, and GPRS data transmission. In the event of auditory hallucinations, the module transmits the patient’s geographical location to relatives or emergency assistance centers.It should be noted that certain components may not be available in the technical drawing software library; therefore, similar components have been substituted in the circuit schematic for illustrative purposes.Examples

[0009] Industrial Applicability

[0010] The invention is specifically for schizophrenia patients with auditory hallucinations, which helps the patient distinguish hallucinations from reality. This invention is used in hospitals, psychology and psychiatric clinics, homes, workplaces, clubs, universities, open spaces, etc., for schizophrenia patients, and it can be purchased through hospitals, pharmacies, medical equipment stores, and websites.Reference Signs List

[0001] 1. Smart glasses (overall design)1-2. Image-processing cameras (Raspberry Pi Al cameras)1-3. Thermal imaging camera module1-4. Flashing LED lights (white and green)1-5. OLED display module (0.91 -inch monochrome)1 -6. Switches for power and settings control1-7. Vibration motors on temple arms1-8. Speakers on temple arms1-9. Lithium battery charge control module1-10. SD card reader module (for SIM and memory cards)1-11. Microphone module1-12. Processor (Raspberry Pi 4)1-13. Lithium battery1 -14. Body temperature detection sensor (MAX30205)1 -15. Pulse oximeter and heart rate sensor (MAX30100)1-16. GSM module (SIM800L, SMS / voice / GPRS)Reference to Deposited Biological Material

[0012] Sequence Listing Free Text

[0013] Citation List

[0014] Patent Literature

[0015] PTL1: WO2021151188 [2021, Canada] - Tool for assisting individuals experiencing auditory hallucinations to differentiate between hallucinations and ambient soundsPTL2: CN105816170B [2016, China] - Schizophrenia early detection assessment system based on wearable NIRS-EEGPTL3: IN202211072524 [2022, India] - An loT-based aid for monitoring hallucinations and assisting in cognitive rehabilitation of schizophrenia patients PTL4: CN104545939A [2015, China] - Head-wearing schizophrenia auxiliary diagnosis devicePTL5: US20220218198A1 [2022, United States] - Method and system for measuring pupillary light reflex with a mobile phonePTL6: US10016130B2 [2018, United States] - Eye tracker system and methods for detecting eye parametersPTL7: US20220095974A1 [2022, United States] - Mental state determination method and systemPTL8: CN109223006A [2019, China] - System for diagnosing schizophreniaPTL9: W02023037708A1 [2023, Japan] - A system, computer program and methodPTL10: KR20190033145A [2019, South Korea] - System for healthy lifestyle for schizophrenia patients using application on smart devicePTL11: CN112168187A [2021, China] - Diagnosis index, diagnosis model and diagnosis system for schizophreniaPTL12: CN112869744A [2021, China] - Schizophrenia auxiliary diagnosis method, system and storage mediumPTL13: RU2766049C1 [2022, Russia] - Method for complex group rehabilitation of patients with schizophreniaPTL14: KR101070122B1 [2011, South Korea] - Device and method for diagnosing schizophrenia using heart rate variability measuresPTL15: US20240285206A1 [2024, United States] - Device and method for dynamic determination of medical subtype, and subtype driven personalized medical carePTL16: US20220395222A1 [2022, United States] - Systems and methods for detection and prevention of emergence of agitationPTL17: US2017135577A1 [2017, United States] - Health assessment via eye movement biometricsPTL18: US10258291 [2019, United States] - Systems and methods for evaluation of neuropathologiesPTL19: CN109480865A [2019, China] - System for diagnosing schizophrenia by utilizing eye movement indexPTL20: CN112057087A [2020, China] - Method and device for evaluating autonomic nerve function of schizophrenia high-risk populationPTL21: KR1020210015365 [2021, South Korea] - Al speaker capable of diagnosing and treating schizophreniaPTL22: JP2008206830A [2008, Japan] - Schizophrenia diagnosing apparatus and programPTL23: CN117617973 [2024, China] - Eye movement feature self-adaption-based schizophrenia early recognition method and system PTL24: WO2016038937A1 [2016, Japan] - Mental disease determination device and mental disease determination methodPTL25: CN110097930A [2019, China] - Schizophrenia medical data processing method, device, system, server and mediumPTL26: US11763929 [2023, United States] - Medical tool aiding diagnosed psychosis patients in detecting auditory psychosis symptoms associated with psychosisPTL27: US0040356A1 [2011, United States] - Methods for treating psychiatric disorders using light energyPTL28: US20210204853 [2021, United States] - Systems and methods for cognitive diagnostics in connection with major depressive disorder and response to antidepressantsPTL29: US5963294A [1999, United States] - Method for using therapeutic glasses for stimulating a change in the psychological state of a subject PTL30: CN213758220U [2021, China] - Human body state monitoring device and braceletPTL31: US10349899B2 [2019, United States] - System and method for predicting hallucinationsPTL32: US11245996B1 [2022, United States] - Apparatus and method for treating a neurological disorder of the auditory systemNon Patent Literature

[0016] NPL1: Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia bulletin, 44(6), 1195-1203.NPL2: Humpston, C. S. (2022). Isolated by oneself: Ontologically impossible experiences in schizophrenia. Philosophy, Psychiatry, & Psychology, 29(1), 5-15.NPL3: Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric disease and treatment, 519-534.NPL4: Bhandari, S. (2012). 6-Descriptive psychopathology. Core Psychiatry (Third Edition)[lnternet], Oxford: WB Saunders, 83-93.NPL5: Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. Lancet (London, England), 388(10039), 86-97.NPL6: Grace, A. A., & Gomes, F. V. (2019). The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention. Schizophrenia bulletin, 45(1), 148-157.NPL7: Thakkar, K. N., Brascamp, J. W., Ghermezi, L., Fifer, K., Schall, J. D., & Park, S. (2018). Reduced pupil dilation during action preparation in schizophrenia. International Journal of Psychophysiology, 128, 111-118.NPL8: Kanungpairn, T., Sitthimongkol, Y., Wattanapailin, A., & Klainin, P. (2007). Effects of a symptom management program on auditory hallucinations in Thai outpatients with a diagnosis of schizophrenia: A pilot study. Nursing & Health Sciences, 9(1), 34-39.NPL9: Cooklin, R., Sturgeon, D., & Leff, J. (1983). The relationship between auditory hallucinations and spontaneous fluctuations of skin conductance in schizophrenia. The British Journal of Psychiatry, 142(1), 47-52.NPL10: Shiloh, R., Munitz, H., Portuguese, S., Gross-lsseroff, R., Sigler, M., Bodinger, L., Katz, N., Stryjer, R., Hermesh, H., & Weizman, A. (2005). Corneal temperature in schizophrenia patients.NPL11: Gabinio, T., Ricci, T. G., Kahn, J. P., Malaspina, D., & Veras, A. B. (2017). Panic psychosis: paroxysmal panic anxiety concomitant with auditory hallucinations in schizophrenia. Revista Brasileira de Psiquiatria, 39(1), 85-86. NPL12: Atsariyasing, W., & Goldman, M. B. (2014). A systematic review of the ability of urine concentration to distinguish antipsychotic-from psychosis-induced hyponatremia. Psychiatry research, 217(3), 129-133.NPL13: Ward, H. B., Nemeroff, C. B., Carpenter, L., Grzenda, A., McDonald, W. M., Rodriguez, C. I., & Kraguljac, N. V. (2023). Substance use disorders inschizophrenia: Prevalence, etiology, biomarkers, and treatment. Personalized Medicine in Psychiatry, 39, 100106.NPL14: Butter, S., Murphy, J., Shevlin, M., & Houston, J. (2017). Social isolation and psychosis-like experiences: a UK general population analysis. Psychosis, 9(4), 291-300.NPL15: Shiloh, R., Munitz, H., Stryjer, R., & Weizman, A. (2007). A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients — a longitudinal study. European neuropsychopharmacology, 17(6-7), 478-482.NPL16: Huang, H., Dong, M., Zhang, L., Zhong, B.-L., Ng, C. H., Ungvari, G. S., Yuan, Z., Meng, X., & Xiang, Y.-T. (2019). Psychopathology and extrapyramidal side effects in smoking and non-smoking patients with schizophrenia: Systematic review and meta-analysis of comparative studies. Progress in NeuroPsychopharmacology and Biological Psychiatry, 92, 476-482.NPL17: Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Archives of general psychiatry, 62(3), 247-253.NPL18: Farwell, W. R., Stump, T. E., Wang, J., Tafesse, E., L’ltalien, G., & Tierney, W. M. (2004). Weight gain and new onset diabetes associated with olanzapine and risperidone. Journal of general internal medicine, 19, 1200-1205. NPL19: Howes, O. D., McCutcheon, R., Agid, O., De Bartolomeis, A., Van Beveren, N. J., Birnbaum, M. L., Bloomfield, M. A., Bressan, R. A., Buchanan, R. W., & Carpenter, W. T. (2017). Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of psychiatry, 174(3), 216-229.NPL20: Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V., Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., & Henderson, C. (2016). The economic burden of schizophrenia in the United States in 2013. The Journal of clinical psychiatry, 77(6), 5379.NPL21: Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., & Fratiglioni, L. (2011). Cost of disorders of the brain in Europe 2010. European neuropsychopharmacology, 27(10), 718-779.NPL22: Buccheri, R., Trygstad, L., Dowling, G., Hopkins, R., White, K., Griffin, J. J., Henderson, S., Suciu, L., Hippe, S., & Kaas, M. J. (2004). Long-term effects of teaching behavioral strategies for managing persistent auditory hallucinations in schizophrenia. Journal of psychosocial nursing and mental health services, 42( ), 18-27.NPL23: Wahyuningtyas, D., Mualifah, L., & Aziz, A. (2022). Effectiveness of Classical Music Therapy to Reducing Auditory Hallucinations in Schizophrenic Patients. 3rd Borobudur International Symposium on Humanities and Social Science 2021 (BIS-HSS 2021),NPL24: Emiroglu, B., Karadayi, G., Aydemir, O., & llcok, A. (2009). validation of the Turkish version of the" Functional Remission of General Schizophrenia"(FROGS) Scale. Noropsikiyatri Arsivi-Archives of Neuropsychiatry, 46, 15-24.

Claims

Claims

1. Smart glasses for detecting auditory hallucinations in schizophrenia patients, aimed at controlling and improving symptoms during disease exacerbation, which consist of a set of electronic components. The purpose of this invention is to help schizophrenic patients distinguish auditory hallucinations from reality, control and relieve the patient's symptoms, send the patient's geographical location and history to family members and emergency teams, manage the patient's treatment process, and provide a complete report of the patient's condition during treatment to the doctor. It is made up of the following components: Smart glasses design shape (1), Image processing camera (1- 2), Thermal camera (1-3), Flashing LED (1-4), 0.91 -inch monochrome OLED display module (1-5), Key or switch (1-6), Coin-type vibration motors (1-7), Speaker or loudspeaker (1-8), Lithium battery charge control module (1-9), SD Card Reader module with read and write capabilities (1-10), Microphone module (1-11), Raspberry Pi 4 processor (1-12), Lithium battery (1-13), Body temperature detection sensor (1-14), Pulse oximeter and heart rate sensor (1- 15), GSM module with SMS and GPRS capabilities (1-16), SIM800L quad-band model (1-16).

2. According to claim number 1, the glasses are calibrated according to the physiological signs of the individual's body under normal conditions, including heart rate, body temperature, corneal temperature, eye deviation, and blood oxygen level.

3. According to claims 2 and 1, the glasses constantly monitor the physiological reactions of the patient's body; eye deviation symptoms are monitored by an image processing camera, corneal temperature by a thermal camera, body temperature by a body temperature detection sensor, and heart rate and blood oxygen levels by a pulse oximeter sensor and a heart rate sensor, and when changes occur in these symptoms compared to the calibrated and normal state (at least 3 out of the 5 physiological symptoms mentioned change), theaforementioned sensors and modules send a command to the glasses' main processor.

4. According to claims 3 and 2, 1 , at this stage, when the sensors detect changes in the physiological signs of the patient's body, the processor sends commands to the speaker or loudspeaker, the SD card reader module with read and write capabilities, and the microphone module; at this time, a question is asked to the user through the speakers: "Do you think you are experiencing an auditory hallucination?". When the user answers "no" to this question, the microphone processes the answer, and the device continues to function normally. When the user answers "yes" to this question, the voice assistant informs him / her through the speakers that he / she is experiencing an auditory hallucination.

5. According to claim number 4, the patient may have been exercising or in a stressful environment and similar conditions; the reason for asking the user above ("Do you think you are experiencing auditory hallucinations?") is to determine whether the change in the user's physiological symptoms was due to a change in the user's conditions and environment or the occurrence of auditory hallucinations.

6. According to claim 5 and 4, 3, 2, 1, at this stage, the processor has detected that the patient is experiencing an auditory hallucination and sends commands to the flashing LED, the coin-type alert notification vibration motors, the speaker or loudspeaker, and the SD Card Reader module with read and write capabilities; at this time, the white and green flashing LED lights and the cointype alert notification vibration motors on the temple arms of the glasses are activated, and classical music with a frequency of 80 Hz or a personalized sound is played from the speakers to help the patient distract his attention from the auditory hallucinations, control and reduce the symptoms of the hallucinations; in fact, the glasses will control and relieve the symptoms of the patient with schizophrenia.

7. According to claims 6 and 5, 4, 3, 2, 1, while diagnosing, controlling, and alleviating the symptoms of schizophrenia, the processor sends a command to the GSM SIM card-enabled module, and the module starts locating the user; after detecting the user's geographical location, the module receives the person's physiological information (heart rate, blood oxygen level, body temperature, corneal temperature, and eye deviations) from the processor and sends it to family members and emergency groups in the form of SMS and calls, along with the person's geographical location, so that the family members are informed of the patient's condition.

8. When a person experiences an auditory hallucination, all the details of the user's information, including the general history, the rate of changes in physiological symptoms (including eye deviation, heart rate, blood oxygen level, corneal temperature, and body temperature), location, date, time, and number of occurrences of auditory hallucinations, and environmental sounds recorded by the microphone, are stored on a memory card via an SD Card Reader module with read and write capabilities so that it can be used by doctors, specialists, and even researchers as a patient history for the user's subsequent use in treatment processes. In fact, in this section, the management of the patient's treatment process and the provision of a complete report of the patient's condition during the treatment period are carried out by the glasses.

9. A display is also used to show the battery charge level of the glasses, display the glasses' antenna, and change the volume of the speakers in the temple arms of the glasses, i